-
Reshaping the Respiratory Medication Market: A $450 Million Acquisition
In a significant move that is set to reshape the respiratory medication market, pharmaceutical company SitoBiotech has announced its acquisition of a ...
2024-03-05 15:55 -
Can AI Save a Giant Pharmaceutical Player with a 90% Market Value Plunge?
In a stunning move, GinkgoBioworks, a synthetic biology giant, has recently announced the acquisition of two AI-driven pharmaceutical startups, Reveri...
2024-03-05 15:50 -
Akeso Inc. Achieves First Annual Profit, Exceeding 1.85 Billion Yuan
In a significant milestone for Akeso Inc., the company has announced its first annual profit, surpassing 1.85 billion yuan.
2024-03-05 15:47 -
Celebrating Profitability: Akeso Bio's Remarkable Turnaround
Akeso Bio, a leading global company specializing in innovative biopharmaceuticals, has achieved a significant milestone by recording its first annual ...
2024-03-05 15:45 -
Controversy Surrounding Improper Use of Semaglutide Triggers Concerns over GLP-1 Production: A Deep ...
In recent days, the pharmaceutical market has been buzzing with new developments.
2024-03-04 14:57 -
The Rise of Telemedicine: Revolutionizing Healthcare Delivery
In recent years, telemedicine has emerged as a game-changer in the field of healthcare.
2024-03-04 14:56 -
The Race for China's First ASO Drug: Who Will Take the Lead?
In the world of antisense oligonucleotide (ASO) drugs, China is eagerly awaiting the development of its first domestically produced ASO medication.
2024-03-04 14:55 -
Unleashing the Potential of OX40: The Next Challenger to Dupilumab
In recent developments, Sanofi has registered a Phase 2 open-label, long-term study on the Chinese Clinical Trial Registry platform.
2024-03-04 14:54 -
Comparative Advantage of BeiGene Baiyueze® MAIC Results over Alectinib!
In recent news from BeiGene, the MAIC (Matching-Adjusted Indirect Comparison) results of Baiyueze® (Zebutinib) have showcased its advantages over ale...
2024-03-04 14:53 -
Soaring by 223%: Hengrui Medicine's Immuno-Oncology Business Doubles Total Revenue in 2023
In a groundbreaking achievement, Hengrui Medicine, a renowned pharmaceutical company, witnessed a remarkable surge of 223% in its immuno-oncology busi...
2024-03-01 13:59
Hot News
- BASF’s Big Restructuring: Cut... Sep 01, 2025
- DuPont Bids Farewell to Its Ar... Sep 02, 2025
- Glenmark Recalls Over 110000 B... Aug 24, 2025
- FDA Clears Sanofi’s Wayrilz (... Aug 31, 2025
- Wanhua Chemical Boosts TDI Cap... Aug 24, 2025
Related Products
Related Producers
